Order Revofil®Ultra for Clinics

Revofil®Ultra is a cross-linked hyaluronic acid dermal filler formulated with biomimetic peptides for deep volume support, contour refinement, and pronounced fold correction. Licensed clinics and healthcare professionals can order Revofil®Ultra for professional treatment-room use, with each prefilled sterile syringe typically containing 1 mL of gel. Its deep-plane application profile makes it most relevant for practices building structured facial volumization protocols rather than superficial hydration-only plans.

Ready to order? Choose your quantity above, or call 1-800-630-9757 to talk to our customer service team.

Revofil®Ultra Price, Account Access, and Unit Selection

Current prices and quantity breaks are shown on this page, and licensed clinics can order as a guest or with an account.

Each syringe is typically supplied as 1 mL of sterile gel. When planning par levels, account for expected consultation volume, common correction patterns, injector technique, and whether the product will be used as a primary deep-volume filler or reserved for selected facial contouring cases. Avoid building purchasing assumptions from keyword variants such as 10 mL unless the active ordering screen and package documentation for the actual unit confirm the presentation.

Quick tip: Match order quantities to scheduled treatment days, staff credentialing, and lot rotation procedures.

What Revofil®Ultra Is and How It Works

Revofil®Ultra is a hyaluronic acid filler designed for structural correction in the deep dermis or subcutaneous plane when administered by trained injectors. Hyaluronic acid is a water-binding polysaccharide used in many soft-tissue fillers because it can provide temporary volume and support within treated tissue. The cross-linked gel structure helps the material maintain shape after placement, while professional injection technique determines the safety and aesthetic quality of the final result.

The formula is enriched with biomimetic peptides, a feature associated with the Revofil portfolio. These peptides are included to support the product’s intended tissue-support profile and firmness characteristics. They do not replace injector assessment, anatomical knowledge, aspiration or cannula decisions, aftercare instructions, or complication protocols.

For a deeper ingredient-focused discussion of this product family, see Revofil filler ingredients and effectiveness. Clinics comparing HA filler behavior across product lines may also review hyaluronic acid in aesthetic medicine for broader class context.

Professional Applications in Aesthetic Practice

This filler supports professional facial contouring and softening of pronounced lines and folds when placed at the appropriate depth. Common clinic-use contexts include midface volume support, nasolabial fold refinement, marionette fold correction, and lower-face contour definition. Lip treatment requests should be assessed cautiously and product choice should follow the injector’s training, the manufacturer’s directions, tissue characteristics, and the patient-specific risk profile.

Revofil®Ultra can be incorporated into staged treatment plans with other HA fillers when rheology, plane of placement, and treatment goals differ by area. For practices building a Revofil-centered formulary, the Revofil brand range can help staff evaluate adjacent products in the same portfolio. When a lighter correction profile is needed, Revofil Fine may be considered for suitable protocols. For moderate correction needs, Revofil Plus offers another Revofil option for professional comparison.

Deep-plane fillers should be integrated into a complete consultation workflow that covers facial anatomy, vascular risk, asymmetry, prior filler history, skin quality, patient expectations, and post-treatment instructions. The product can provide immediate visible volume, but transient swelling, bruising, tenderness, or early asymmetry may affect the first chairside assessment.

Key Features for Clinic Workflows

• Cross-linked HA gel: supports structural volume and contour work in deeper tissue planes.
• Peptide-enriched formulation: aligns with the Revofil portfolio’s biomimetic peptide approach.
• Prefilled sterile syringe: typically supplied as a 1 mL unit for single-use professional administration.
• Deep placement profile: intended for the deep dermis or subcutaneous plane by trained clinicians.
• Controlled extrusion: predictable syringe behavior can support consistent injector workflow.
• Traceable packaging: lot and expiration information support clinic inventory records.
• Professional-use restriction: not appropriate for consumer self-administration.

These features make the product most suitable for practices with established injectable protocols, adverse-event escalation procedures, and injector competency in deep soft-tissue filler placement. Standardized treatment notes, photography routines, and lot documentation help multi-injector teams maintain consistency across locations.

Composition, Packaging, and Handling

The active component is cross-linked hyaluronic acid gel enriched with biomimetic peptides. Full excipient information, needle recommendations, expiration dating, and lot-specific specifications should be confirmed against the manufacturer packaging and technical insert supplied with the unit. If anesthetic content matters for a protocol, verify the presence or absence of lidocaine directly on the printed label for the shipped lot.

The sterile prefilled syringe is intended for single use with aseptic technique. Do not resterilize, share syringes between patients, or use damaged packaging. Clinic teams should record lot number, expiry, treatment area, volume used, injection plane, device or needle/cannula selection, and injector name according to the practice’s documentation standards.

Storage and transport should follow the manufacturer’s instructions for the specific lot. Our logistics process can include temperature-controlled handling when required and tracked US delivery. Receiving teams should inspect outer packaging, reconcile the shipment against the purchase order, and move product into approved storage promptly.

Safety, Contraindications, and Monitoring

Hyaluronic acid dermal fillers should be administered only by trained healthcare professionals who understand facial anatomy and filler complication management. Common post-injection effects may include swelling, redness, bruising, tenderness, itching, firmness, or temporary unevenness at the injection site. These reactions are often local and time-limited, but clinics should give clear aftercare instructions and document patient communication.

Important risks include infection, inflammatory nodules, hypersensitivity reactions, vascular occlusion, tissue ischemia, scarring, and, in rare circumstances, vision-related complications if material enters or compresses critical vessels. Practices should maintain protocols for urgent assessment, hyaluronidase use when clinically appropriate for HA filler complications, referral pathways, and follow-up monitoring.

Contraindication screening should cover active skin infection or inflammation at the treatment site, known hypersensitivity to product components, bleeding risk, anticoagulant use, immune status, pregnancy or breastfeeding considerations, and recent procedures that could affect healing. The final decision to inject, defer, combine, or choose an alternative filler should rest with a qualified clinician after assessment.

For patient education and expectation-setting, clinic staff may find dermal filler misconceptions useful when preparing consultation materials. Internal education should still be based on manufacturer instructions, professional training, and current standards of care.

Ordering and Logistics for Licensed Practices

Create or verify your clinic account to access current procurement terms and ordering information. US distribution supports practical inventory planning for single-location and multi-site aesthetic practices.

Because this is a professional injectable, internal controls matter as much as unit selection. Assign purchasing permissions, limit treatment-room access to qualified staff, and separate clinical decision-making from inventory substitution requests. If a preferred lot or unit configuration changes, our customer service team can help identify adjacent products for the clinical team to evaluate, but the injector should decide whether any substitution fits the planned treatment map.

Practices expanding their injectable menu may also review wholesale dermal fillers for aesthetic practices for category-level procurement considerations. This can support formulary planning, staff training conversations, and inventory standardization across filler types.

Comparable Revofil and Adjacent Options

Revofil®Ultra is positioned for deeper structural support, while other Revofil products may be better aligned with lighter correction, skin quality programs, or area-specific protocols. The right product depends on placement depth, tissue thickness, desired lift, injector technique, and whether the plan emphasizes contour, fold softening, hydration, or overall skin appearance.

Clinics evaluating texture and hydration-focused follow-up can consider Revofil Aquashine Soft Filler as a separate Revofil option. For practices comparing Revofil against another major HA filler family, Revofil versus Juvéderm selection factors can support internal discussion about rheology, treatment goals, and provider preference without replacing clinical judgment.

Do not assume that fillers are interchangeable solely because they contain hyaluronic acid. Cohesivity, particle or gel structure, extrusion force, intended plane, and labeled directions can differ meaningfully. Substitution decisions should be documented and communicated within the clinical team before the treatment appointment.

Authoritative Sources for Professional Review

Clinics should rely on the manufacturer’s professional overview, current package insert, and lot-specific documentation for final product specifications, administration directions, storage requirements, contraindications, and adverse-event reporting procedures. General regulator materials on soft-tissue fillers can help teams frame consent discussions, complication awareness, and safe administration policies.

Peer-reviewed literature on HA filler rheology, facial anatomy, injection planes, and vascular adverse events can support staff education and protocol development. Use those sources to strengthen training programs, not to override the manufacturer’s directions for a specific product lot.

This content is for informational purposes only and is not a substitute for professional medical advice.